Member Survey Summary, June 2023

In March of 2022 NASCSA conducted a survey of it’s state members requesting their input on a recent petition submitted Public Citizen to the FDA and DEA to place gabapentin and gabapentin enacarbil on schedule V of the Controlled Substances Act. Attached please find the results of the survey that showed overwhelming support for rescheduling the drug to Schedule V and a letter to FDA sharing the survey results.
NASCSA Gabapentin Survey, March 2022

COVID - 19 SURVEY, August 4 2020

NASCSA 2020 PMP SURVEY, January 12 2020